SM
CCCC icon

SG3 Management’s C4 Therapeutics CCCC Stock Holding History

SG3 Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-77,600
Closed -$585K – 319
2022
Q2 		$585K Hold
77,600
– – 0.07% 189
2022
Q1 		$1.88M Buy
+77,600
New +$1.88M 0.05% 307

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

SG3 Management's CCCC Position: Q2 2022 in Review

SG3 Management sold out of C4 Therapeutics (CCCC) in Q2 2022, closing a stake of 25,000 shares — an estimated $220K sold.

SG3 Management first reported a position in CCCC in Q1 2022 and held it in 1 quarter. The position peaked at $607K in Q1 2022. 113 funds tracked by Wall St. Rank hold CCCC as of Q2 2022.

  • SG3 Management reported no remaining C4 Therapeutics position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 25,000 C4 Therapeutics shares in Q2 2022, an estimated $220K.
  • SG3 Management first reported a position in C4 Therapeutics in Q1 2022 and held it in 1 quarter.
  • SG3 Management's C4 Therapeutics position peaked at $607K in Q1 2022.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.